132 results about "Inflammasome" patented technology

The invention relates to the molecular biology field and particularly relates to a gene knockout carrier, a construction method and application thereof and a gene knockout method of an NLRP1 gene of an MH7A cell. A CRISPR-Cas9 gene knockout system is utilized for carrying out CRISPR targeting sequence design by taking NLRP1 as a target gene so as to prepare a knockout carrier aiming at the NLRP1 gene, and the knockout carrier is utilized for transfecting the MH7A cell, so that the NLRP1 gene in the MH7A cell can be efficiently knocked out; and therefore, a research platform for rheumatoid arthritis is effectively built, so that the research of the pathogenesis of the rheumatoid arthritis is greatly promoted, and the researches of the interaction of NLRP1 inflammasomes and various inflammatory factors and the disease related molecular mechanisms of the rheumatoid arthritis and meningitis can be promoted.

The invention relates to application of oridonin in preparing drugs for preventing or treating NLRP3 inflammasome-related diseases. The oridonin has a strong pharmacological effect, is safe and innoxious, and indicates a good medicinal prospect. The oridonin can inhibit the activation of an NLRP3 inflammasome in vitro, and can treat pathological conditions of NLRP3 inflammasome-related disease model in vivo. The oridonin can be directly combined with NLRP3 through covalent bonds, thereby inhibiting the interaction of the NLRP3 and NEK7, inhibiting the assembly of the inflammasome, and achieving the purpose of inhibiting the activation of the inflammasome.

The present invention provides compositions and methods for treating or preventing an NLRP3 immunosome-related disorder. In one embodiment, the method includes administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibitor to a subject in need thereof.

The invention includes novel methods of treating or preventing fibrosis in a subject afflicted with scleroderma, comprising administering to the subject a therapeutically effective amount of an agent that inhibits formation of at least one inflammasome signaling product in the subject.

The invention provides a probe set and a kit for detecting a pathogenic gene of an autoinflammatory disease. The probe set comprises probes capable of simultaneously specifically capturing pathogenicgenes affecting inflammasome defects, non-inflammasome defects and autoinflammatory diseases associated with defects in an interferon pathway. The probe set and the kit for detecting the pathogenic gene of the autoinflammatory disease are capable of simultaneously detecting the pathogenic genes of 50 types of known autoinflammatory diseases; based on the probe set which is high in targeted screening, stable and reliable in gene acquisition and used for detecting the pathogenic gene of the autoinflammatory disease, and combined with a high-throughput sequencing method, a diagnosis cycle of theautoinflammatory disease can be accelerated, the diagnostic efficiency can be improved, and several new diseases can be diagnosed, especially for children with the autoinflammatory diseases, so that the effects of no missed detection, no missed diagnosis, relatively small amount of data analysis, shortened inspection cycle are achieved.

The invention belongs to the field of biomedicine, and relates to a fusion protein for sub-cellular localization and an application thereof. A system can be used for reporting the activity of inflammasomes on the organelle level mainly based on secretion type luciferase. 7 kinds of plasmids included in the system are mainly obtained by sequentially cloning an organelle localization gene, an interleukin 1beta precursor coding gene (pro-IL-1beta) and secretion type luciferase (DN-Gluc) to a multiple cloning site zone of an expression vector pcDNA3.1. The plasmids included in the system are transfected to target cells respectively, and the activity of the inflammasomes can be quantitatively analyzed by detecting the activity of luciferase in extracellular supernate, so that the system has the advantages of high efficiency, fastness, simplicity, convenience and the like and can be applied to medicament screening, molecular mechanisms, live animal research and development of related products related to the inflammasomes.

The invention relates to application of disulfiram in preparing drugs for preventing and treating diseases related to NLRP3 inflammasome. During research, phenomena are found that the disulfiram can effectively inhibit activation of the NLRP3 inflammasome and inhibit maturation and secretion of an inflammatory activation signal molecule Caspase-1P20 and an inflammatory cytokine IL-1[beta], accordingly has good prevention and treatment effects on the diseases related to the NLRP3 inflammasome, and especially has significant prevention and treatment effects on peritonitis and gouty arthritis.

The invention discloses application of echinatin serving as an inflammation inhibitor. The echinatin can serve as an inflammasome inhibitor, and can inhibit formation of apoptosis-associated speck-like protein (ASC) spots as well as subsequent activation of caspase-1 p20 and secretion of IL-1beta. The echinatin can serve as a potential drug for treating of diseases related to abnormal activation of inflammasomes.

The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I):

wherein R¹, R², R³, R⁴, R⁵ and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

The invention discloses application of a hydrogen molecule solid carrier in preparation of medicine for preventing and treating obesity related metabolic inflammation. According to the hydrogen molecule solid carrier, molecular hydrogen achieves a physiological effect, the carrier does not achieve the physiological effect, the reducing effect of hydrogen can be fully achieved, and prevention and treatment of obesity related metabolic inflammation are achieved from multiple levels. The application includes the steps of inhibiting increase of serum inflammatory factors in the generating process of obesity related metabolic inflammation, inhibiting increase of adipose tissue inflammatory factors, relieving adipose tissue dyslipidemia, inhibiting generation of oxidative damage in adipose tissue and inhibiting activation of inflammasome in the adipose tissue. The result shows that the hydrogen molecule solid carrier is fairly effective medicine for preventing and treating obesity related metabolic inflammation.

The invention discloses an application of an exosome in preparation of drugs or cosmetics for repairing skin injury, belonging to the technical field of skin treatment. In order to solve the problem of skin injury, the exosome provided by the invention is obtained through the following steps: separating mesenchymal stem cells from primary cornu cervi pantotrichum tissues; and carrying out in-vitroamplification culture, collecting a cell culture solution, and carrying out separation and extraction so as to obtain an antler mesenchymal stem cell-derived exosome. The exosome provided by the invention is proved to be able to inhibit LPS induced inflammatory response of HaCat cells through an NLRP3 inflammasome signaling pathway, accelerate wound repair of a mouse model with skin injury and relieve inflammatory response. The exosome provided by the invention can be used for preparing the drugs or the cosmetics for treating skin injury repairing.

The invention relates to the technical field of new applications of drugs and especially relates to an application of panax notoginseng saponins in preparing NLRP3 inflammasome-restraining drugs or drugs for treating tristimania. A test result proves that panax notoginseng saponins is capable of obviously restraining activation of LPS-induced rat hippocampal microglia and release of NLRP3 inflammasome and IL-1 beta and IL-18 and can be used for treating tristimania induced by abnormal increasing of microglia NLRP3 inflammasome.

The invention discloses application of BRLF1 in the preparation of preparations to inhibit activity of Herpes virus-activated inflammasomes, and also discloses a BRLF1 functional small peptide which may act on inflammasome activity pathways and has a broad-spectrum inhibitory function for the activity of inflammasomes. After a small peptide is conjugated with and passed through a signal peptide, good penetrating property is provided; the functional small peptide can enter cells directly to better give rise to the effect of inhibiting the activity of inflammasomes.

The invention relates to a class of 1, 2, 3, 5, 6, 7 hexahydrosymmetric indacene compounds containing one or more substituents., pharmaceutically acceptable salts, esters or hydrates thereof, a preparation method thereof, a pharmaceutical composition containing the compounds, and an application of the compounds as a novel NLRP3 inflammasome inhibitor in preparation of drugs for preventing and/or treating diseases related to NLRP3 inflammasome.

The invention discloses application of a Compound C in preparation of a medicine used for treating a non-alcoholic fatty liver disease (NAFLD). Experimental results show that the Compound C is provedto be capable of effectively inhibiting NLRP3 inflammasome and inflammation reaction by virtue of experiments, so that formation of the NAFLD is obviously reduced. Therefore, a research foundation anda theoretical basis are provided for development of medicines used for treating the NAFLD.

A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.

The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease. The present inventors also established the inflammasome inhibitor rhIL1RA or Z-YVAD-FMK by using the above GM1 cell model and further confirmed that it can be efficiently used as a relieving/treating agent of GM1 gangliosidosis.

In addition, the molecular symptoms of GM1 patient could be reproduced in the transformed cells having the E186A mutation which is newly identified as the GM1 gangliosidosis causing protein mutation. Therefore, the mutant cells containing the induced E186A mutation can be efficiently used as the GM1 gangliosidosis cell model.